Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion AB's change in inventory for the quarter that ended in Jun. 2026 was kr-2.3 Mil. It means Xvivo Perfusion AB's inventory
increased by kr2.3 Mil
from Mar. 2026 to Jun. 2026 .
Xvivo Perfusion AB's change in inventory for the fiscal year that ended in Dec. 2025 was kr-37.9 Mil. It means Xvivo Perfusion AB's inventory
increased by kr37.9 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Xvivo Perfusion AB's Days Inventory for the quarter that ended in Jun. 2026 was 298.78.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Xvivo Perfusion AB's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xvivo Perfusion AB's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.95.
Xvivo Perfusion AB (CHIX:XVIVOs) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Xvivo Perfusion AB's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xvivo Perfusion AB's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Change In Inventory Related Terms
Xvivo Perfusion AB Change In Inventory Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr32.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of kr32.0 Mil mean?
Xvivo Perfusion AB (CHIX:XVIVOS) has a Change In Inventory of kr32.0 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Change In Inventory too high?
Xvivo Perfusion AB's current Change In Inventory is kr32.0 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Change In Inventory compare to ABT and SYK?
Xvivo Perfusion AB's Change In Inventory of kr32.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Devices & Instruments company?
A good Change In Inventory depends on the Medical Devices & Instruments industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Change In Inventory is kr32.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Xvivo Perfusion AB (CHIX:XVIVOS) has a current Change In Inventory of kr32.0 Mil. The stock's GF Value™ is kr512.75, compared to a current price of kr302.60 — trading 41% below its estimated fair value. The current Change In Inventory is kr32.0 Mil. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Xvivo Perfusion AB (CHIX:XVIVOS), the current Change In Inventory is kr32.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (CHIX:XVIVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of kr302.60 is trading 41% below its estimated GF Value™ of kr512.75.
Key valuation signals for CHIX:XVIVOS:
Change In Inventory: kr32.0 Mil
GF Value™: kr512.75 vs. price of kr302.60 (41% below fair value)
No single metric tells the full story. See the CHIX:XVIVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for CHIX:XVIVOS
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:XVIVOS has been successfully added to your 
